APA (7th ed.) Citation

Cheon, J., Shimose, S., Kim, H., Niizeki, T., Ryu, M., Shirono, T., . . . Yoo, C. Lenvatinib versus sorafenib as second-line therapy following progression on atezolizumab–bevacizumab in patients with unresectable hepatocellular carcinoma: A multicenter retrospective study from Korea and Japan. Springer.

Chicago Style (17th ed.) Citation

Cheon, Jaekyung, Shigeo Shimose, Hyung-Don Kim, Takashi Niizeki, Min-Hee Ryu, Tomotake Shirono, Baek-Yeol Ryoo, Hideki Iwamoto, and Changhoon Yoo. Lenvatinib Versus Sorafenib as Second-line Therapy Following Progression on Atezolizumab–bevacizumab in Patients with Unresectable Hepatocellular Carcinoma: A Multicenter Retrospective Study from Korea and Japan. Springer.

MLA (9th ed.) Citation

Cheon, Jaekyung, et al. Lenvatinib Versus Sorafenib as Second-line Therapy Following Progression on Atezolizumab–bevacizumab in Patients with Unresectable Hepatocellular Carcinoma: A Multicenter Retrospective Study from Korea and Japan. Springer.